Survodutide Benefits: Claims vs What Studies Show
Benefits people claim for Survodutide, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 7 / 0
- in our evidence file (PubMed search, 2 Oct 2026)
- FDA status
- Not approved
- Investigational · phase 3
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Weight loss | Human RCT evidence, 4 of 4 | 6 / 0 | Body weight at week 76 (coprimary); Body weight; Body weight at week 46 (primary) | Evidence for weight loss |
| Diabetes | Human RCT evidence, 4 of 4 | 2 / 0 | Body weight at week 76 (coprimary); HbA1c; HbA1c vs semaglutide | Evidence for diabetes |
| Liver health | Human RCT evidence, 4 of 4 | 3 / 0 | Liver fat reduction of 30% or more; Body weight; MASH improvement without worsening of fibrosis (primary) | Evidence for liver health |
| Metabolism | Human RCT evidence, 4 of 4 | 1 / 0 | HbA1c | Evidence for metabolism |
| Heart health | Review only | 0 / 0 | Cholesterol, triglycerides and blood pressure | Evidence for heart health |
Strongest study per claim: Weight loss, The New England journal of medicine 2026, PMID 42253238; Diabetes, The New England journal of medicine 2026, PMID 42820639; Liver health, Nature medicine 2026, PMID 42252333.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight at week 76 (coprimary) | Body weight changed by -13.0% with 6.0 mg and -12.2% with 3.6 mg versus -5.4% with placebo at week 76 (treatment-regimen estimand). | Human RCTn = 725 | The New England journal of medicine 2026, PMID 42253238 |
| Body weight at week 76 (coprimary) | Body weight changed by -9.8% with 6.0 mg and -8.2% with 3.6 mg versus -3.9% with placebo. | Human RCTn = 752 | The New England journal of medicine 2026, PMID 42820639 |
| HbA1c | Glycated hemoglobin changed by -0.9 percentage points (3.6 mg) and -0.8 (6.0 mg) versus -0.2 with placebo. | Human RCTn = 752 | The New England journal of medicine 2026, PMID 42820639 |
| Liver fat reduction of 30% or more | 84.2% on survodutide versus 24.3% on placebo had a 30% or greater liver fat reduction (efficacy estimand); 68.5% versus 28.6% (treatment regimen estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| Body weight | Body weight changed by -12.2% with survodutide versus -1.0% with placebo (efficacy estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| Body weight at week 46 (primary) | Body weight changed by -14·9% with 4·8 mg, -13·2% with 3·6 mg, -12·5% with 2·4 mg and -6·2% with 0·6 mg versus -2·8% with placebo at week 46. | Human RCTn = 387 | The lancet. Diabetes & endocrinology 2024, PMID 38330987 |
| MASH improvement without worsening of fibrosis (primary) | MASH improved without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| Liver fat reduction of 30% or more | A 30% or greater liver fat decrease occurred in 63%, 67% and 57% across doses versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| HbA1c vs semaglutide | HbA1c fell by -1.46% with low-dose survodutide (DG2) and -1.47% with semaglutide. | Human RCTn = 413 | Diabetologia 2024, PMID 38095657 |
| Body weight | Body weight fell dose-dependently up to -8.7% (DG6), greater than with semaglutide (-5.3%) for survodutide 1.8 mg weekly or more. | Human RCTn = 413 | Diabetologia 2024, PMID 38095657 |
| Liver and metabolic markers in cirrhosis | Liver fat content, liver stiffness, liver volume and body weight were generally reduced after 28 weeks (non-randomised, open-label). | Human uncontrolled trial | Journal of hepatology 2024, PMID 38857788 |
| HbA1c | Survodutide reduced HbA1c by a weighted mean difference of -0.66% (95% CI -1.08 to -0.23) versus placebo. | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Waist circumference | Survodutide reduced body weight by a mean difference of -6.7 kg and waist circumference by -7.09 cm. | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Cholesterol, triglycerides and blood pressure | Modest reductions were noted in total cholesterol, triglycerides and blood pressure (no figures in the abstract). | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Weight, BMI and waist circumference | Survodutide reduced weight by a mean difference of -8.33 kg, BMI by -4.03 kg/m2 and waist circumference by -6.33 cm versus control (very high heterogeneity). | Meta-analysisn = 1029 | Diabetology & metabolic syndrome 2024, PMID 39508238 |
Claim: it causes more weight loss than GLP-1 drugs alone
In the first phase 3 obesity trial without diabetes, 3.6 mg and 6.0 mg groups lost an average of 12.2% and 13.0%, while placebo lost 5.4%.[1]
Against semaglutide the one head-to-head signal is a phase 2 diabetes trial in which survodutide at 1.8 mg a week or more cut weight further.[6]
A pooled analysis counted a weight difference of -8.33 kg and a waist difference of -6.33 cm against control.[9]
Claim: it controls type 2 diabetes
In adults with obesity and type 2 diabetes, HbA1c fell by 0.9 percentage points in the 3.6-mg group and 0.8 in the 6.0-mg group, with 0.2 on placebo.[2]
Pooled across six trials, survodutide lowered fasting glucagon by 7 pmol/L, an average effect of the compound on its second target.[8]
Claim: it reverses fatty liver and MASH
In the phase 2 MASH trial, 62% on the 4.8-mg dose had MASH improve with no worsening of fibrosis, against 14% on placebo.[5]
The SYNCHRONIZE-MASLD authors list the short 48-week duration and the US-and-Spain recruitment as limits.[3]
Claim: it protects the heart and improves metabolism
The nearest cardiometabolic data are pooled lipid and blood-pressure changes described as modest, not outcome counts.[8]
Claims no cached study backs
The 2 Oct 2026 PubMed search for survodutide returned 86 papers in all, 56 of them with a randomized, trial or phase term, and none of the 8 abstracts cached for this page reports a muscle-gain, anti-ageing or sleep outcome.
Calculated from query survodutide[tiab] OR BI456906[tiab]; date 2026-10-02; count 86; trial term count 56. Formula: counts from the evidence file's search record
More on Survodutide
Common questions
Is Survodutide proven to work?
The strongest study we summarise for Survodutide is human rct evidence, among 9 studies. A trial result is not an approval; see the legal status.
What does survodutide do?
Survodutide is a glucagon receptor and GLP-1 receptor dual agonist under investigation for obesity and related diseases, according to the SYNCHRONIZE-MASLD report.[3]
What benefits has survodutide shown in trials?
The trial benefits reported are weight, HbA1c and liver-fat changes against placebo, along with a high share of gastrointestinal events.[1]
More on Survodutide
Sources
- 1Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
- 2Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
- 3Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
- 4Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
- 5A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
- 6Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026
- 7Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
- 8Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025PMID 40922121Accessed 2 Oct 2026
- 9Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2024PMID 39508238Accessed 2 Oct 2026
- 10PubMed search: survodutide[tiab] OR BI456906[tiab] (86 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (56 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.